Jay Fiore, MD
Ophthalmology · Carla Place, NYNPI 1578708897
Payments from drug & device makers
Across 177 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Bausch & Lomb Americas Inc.$507
- Novartis$368
- Sun Pharmaceutical Industries Inc.$341
- AbbVie$319
- Astellas Pharma US Inc$231
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,44398%
- Education$581%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 41 | $1,198 |
| Bausch & Lomb Americas Inc. | 19 | $507 |
| Novartis | 24 | $368 |
| Sun Pharmaceutical Industries Inc. | 16 | $341 |
| AbbVie(2 entities) | 14 | $319 |
| Astellas Pharma US Inc | 2 | $231 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $220 |
| Tarsus Pharmaceuticals, Inc. | 7 | $215 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $210 |
| Aerie Pharmaceuticals, Inc. | 4 | $164 |
| Ivantis, Inc | 1 | $144 |
| Oyster Point Pharma, Inc. | 7 | $110 |
| Biotissue Holdings Inc. | 4 | $65 |
| Shire North American Group Inc | 3 | $58 |
| Ocular Therapeutix, Inc. | 3 | $57 |
| Amgen(2 entities) | 2 | $52 |
| Dompe US, Inc. | 2 | $46 |
| NEW World Medical,inc. | 3 | $44 |
| Glaukos Corporation | 2 | $42 |
| Thea Pharma Inc. | 2 | $34 |
| Kala Pharmaceuticals, Inc. | 2 | $32 |
| Rxsight Inc | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sight Sciences, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$281
- Constellation$281
- Tecnis Simplicity$147
- MIEBO$145
- XIIDRA$145
- enVista MX60 IOL$145
- Hydrus Microstent$144
- AcrySof IQ VIVITY$141
- Centurion$133
- Izervay$132
- Rhopressa$108
- Rocklatan$108
How this compares
$4,520 in reported general payments places this provider in the 75th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 23 | $645,464 |
| RestasisCyclosporine | 81 | $80,943 |
| XiidraLifitegrast | 60 | $69,575 |
| LumiganBimatoprost | 93 | $47,574 |
| Cyclosporine | 70 | $39,116 |
| TyrvayaVarenicline Tartrate | 37 | $32,312 |
| Prednisolone Acetate | 641 | $30,832 |
| Fluorometholone | 318 | $21,807 |
| ZirganGanciclovir | 34 | $16,582 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 45 | $11,209 |
| RhopressaNetarsudil Mesylate | 26 | $10,892 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $9,485 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $8,788 |
| VyzultaLatanoprostene Bunod | 25 | $8,718 |
| ValacyclovirValacyclovir Hcl | 111 | $7,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $46 | $645,46423 claims |
| AbbVieRestasis, Lumigan, Combigan | $319 | $137,305194 claims |
| Bausch & Lomb Americas Inc.Xiidra, Zirgan, Vyzulta | $507 | $94,874119 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $110 | $32,31237 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $164 | $20,37850 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $220 | $6,59051 claims |
| Thea Pharma Inc.Iyuzeh | $34 | $3,62613 claims |
| AlconSimbrinza | $1,198 | $2,68312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Carla Place
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.